USC removes name of Rufus von KleinSmid, a eugenics leader, from prominent building
By Teresa Watanabe and Tomás Mier,
Los Angeles Times
| 06. 12. 2020
The scholar, who is credited with expanding the university’s academic programs and international relations curriculum as president from 1921 to 1947, believed that people with “defects” had no ethical right to parenthood and should be sterilized.
With its soaring arches, international flags and globe-topped tower, the Von KleinSmid Center for International and Public Affairs is one of the most prominent buildings at USC. Its namesake, the late Rufus B. von KleinSmid, has held a place of distinction as the university’s fifth president.
But on Thursday, USC announced it had stripped Von KleinSmid’s name from the building as the university at last reconciled with his disturbing leadership role in California’s eugenics movement.
The scholar, who is credited with expanding the university’s academic programs and international relations curriculum as president from 1921 to 1947, believed that people with “defects” had no ethical right to parenthood and should be sterilized. His “Human Betterment Foundation” was instrumental in supporting the 1909 California legislation that authorized the forced sterilization of those deemed “unfit” — essentially anyone non-white, said Alexandra Minna Stern, a University of Michigan history professor and expert on eugenics.
His active support of eugenics is “at direct odds with USC’s multicultural community and our mission of diversity and inclusion,” President Carol L. Folt announced.
“This moment is our Call...
Related Articles
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...